RSS

autologous therapies

Orchard Therapeutics, a commercial and clinical-stage company, has opened a new US office located in Boston’s Seaport District, building upon the company’s footprint in London as well as Foster City and Menlo Park, California. Read more

News

Orchard Therapeutics, a clinical-stage biotechnology company, has acquired an exclusive licence to develop lentivirus-based autologous ex-vivo gene therapy for Sanfilippo syndrome type B (or MPS-IIIB) from The University of Manchester. Read more

News

Lonza has announced its successful acquisition of PharmaCell, a European cell and gene contract manufacturer. Read more

News